Although SCD1 has been considered as a promising target for the treatment of a broad spectrum of human malignancies [7,40], as far as we are aware, this is the first time that a phospholipidomic analysis has been applied in GBM cells after SCD1 silencing. This evidence concerns the gene SCD and glioblastoma.